



(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 25/16 (2006.01)

A61K 31/551 (2006.01) A61P 25/28 (2006.01)

A61P 1/04 (2006.01)

(21) International Application Number:

PCT/IB2013/056782

(22) International Filing Date:

21 August 2013 (21.08.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1215033.0 23 August 2012 (23.08.2012) GB

(71) Applicant (for all designated States except SA, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **BEHNKE, Dirk** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **CARCACHE, David** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **ERTL, Peter** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **KOLLER, Manuel** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **ORAIN, David** [FR/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) Agent: GABARDA, Ana; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE



(57) Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.